Rivaroxaban
Thrombotic Disease
Shanghai Zhongshan HospitalSmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Thrombotic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aspirin China National Center for Cardiovascular Diseases | Phase 4 | BBB |
Apixaban Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Phase 4 | BB |
Dabigatran St. Antonius Hospital | Phase 4 | BB |
WARFARIN China National Center for Cardiovascular Diseases | Phase 4 | BB |
Enoxaparin Helsinki University Central Hospital | Phase 4 | BB |
View all 23 →
Same molecule, other indications
Rivaroxaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →